Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutic
(NQ:
HALO
)
62.17
+1.24 (+2.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutic
< Previous
1
2
3
4
5
6
7
Next >
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
December 19, 2023
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
December 18, 2023
Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced.
Via
Chartmill
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals.
December 08, 2023
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
NASDAQ:HALO is showing good growth, while it is not too expensive.
November 27, 2023
Despite its growth, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains within the realm of affordability.
Via
Chartmill
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
November 24, 2023
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
NASDAQ:HALO, an undervalued stock with good fundamentals.
November 15, 2023
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Earnings Outlook For Halozyme Therapeutics
November 03, 2023
Via
Benzinga
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
November 02, 2023
NASDAQ:HALO, a growth stock which is not overvalued.
Via
Chartmill
NASDAQ:HALO is showing decent growth, but is still valued reasonably.
October 12, 2023
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).
Via
Chartmill
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune
October 27, 2023
Are you looking to invest in the stock market and become a millionaire? Here are three stocks to buy to turn $1,000 into a fortune.
Via
InvestorPlace
For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals.
October 24, 2023
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Analyst Expectations for Halozyme Therapeutics's Future
October 09, 2023
Via
Benzinga
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
October 06, 2023
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Via
Chartmill
Where Halozyme Therapeutics Stands With Analysts
September 08, 2023
Via
Benzinga
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
October 19, 2023
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or...
Via
Benzinga
Why NASDAQ:HALO Is a Standout High-Growth Stock in a Consolidation Phase.
October 11, 2023
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.
Via
Chartmill
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
September 26, 2023
Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
September 26, 2023
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably.
Via
Chartmill
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall
September 23, 2023
Discover the thrill of undervalued and overlooked sleeper stocks poised for growth in a shifting market environment.
Via
InvestorPlace
Expert Ratings for Halozyme Therapeutics
August 15, 2023
Via
Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.
Via
Benzinga
Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market
July 24, 2023
HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ: HALO) with a Buy rating and a
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
July 24, 2023
Via
Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
July 13, 2023
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 20, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.